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PHARMACOKINETICS OF ORAL TACROLIMUS IN RECIPIENTS OF ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Yamazaki, R., Mori, T., Nakazato, T., Aisa, Y., Ikeda, Y., Okamoto, S.
Division of Hematology, Department of Medicine, Keio University School
of Medicine, Tokyo, Japan.
Background: Tacrolimus is an immunosuppressive agent used
for the prevention and treatment of graft-versus-host-disease
(GVHD) in allogeneic hematopoietic stem cell transplantation
(HSCT). In contract to its intravenous formulation, pharmacoki-
netics of oral administered tacrolimus was yet to be fully examined.
Patients /Methods: Recipients of allogeneic HSCT with GVHD
prophylaxis using tacrolimus were eligible. Tacrolimus were initi-
ated by continuous intravenous infusion from day 1, and contin-
ued until patients became capable of taking tacrolimus orally. On
the second day of oral tacrolimus administration, whole blood
concentration of tacrolimus was measured by MEIA before, 30min,
1, 2, 3, 4, 6, and 12 hours after administration. Results: Thirteen
patients were evaluable. Mean blood level before administration
(C0) was 9.851.85 ng/mL. Mean maximum concentration (Cmax)
was 19.812.3 ng/mL, and median Tmax was 3 hours (range; 1–6
hours). Two subgroups were identiﬁed in regard to the difference
between C0 and Cmax; Cmax  C0 10 ng/mL (Group A: n  4)
and Cmax  C0 10 ng/mL (Group B: n  9). Although there was
no signiﬁcant difference in C0 and C12 between the two groups,
mean area under the concentration curve for 12 hours (AUC0–12)
in group A was signiﬁcantly greater than that in group B (204 
51.6 vs 136  22.9 nghr/mL; P  .045). Mean half-life of tacroli-
mus in group A was signiﬁcantly shorter than that in group B
(16.2  8.28 hr vs 42.8  15.5 hour; P  .041). Discussion:
Pharmacokinetics of orally administered tacrolimus did not neces-
sarily show a uniform pattern; and a prominent feature was an
unexpectedly high Cmax and AUC observed in some patients.
However, this phenomenon could not be recognized only by mea-
suring its trough level (C0) because of alteration in its half-life. We
conclude that pharmacokinetic analysis should be performed in
every patient to decide optimal dose of tacrolimus to prevent
overdosing.
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DIFFERENTIAL EFFECTS OF IMMUNOSUPPRESSANTS ON ADOPTIVELY
TRANSFERRED CD4CD25high REGULATORY T CELLS IN PREVENTION
OF EXPERIMENTAL ACUTE GRAFT-VERSUS-HOST DISEASE
Zeiser, R.1, Nguyen, V.1, Beilhack, A.1, Schulz, S.2, Baker, J.1,
Contag, C.H.3, Negrin, R.S.1 1. Stanford University, Department of
Medicine, Stanford, CA; 2.Technische Universitat Munchen, Munchen,
Germany; 3. Stanford University, Department of Pediatrics, Stanford,
CA.
The observation that CD4CD25regulatory T cells (Treg) are
capable of suppressing experimental aGVHD while preserving the
beneﬁcial graft-versus-tumor effect (GVT), fueled interest in ex-
ploring cell-based immunotherapy in clinical trials. However, in
contrast to experimental models of aGVHD, most clinical trans-
plantation protocols include combinations of immunosuppressive
drugs and currently there is no information on the impact of these
drugs on Treg function in vivo. Therefore, we evaluated the
impact of Cyclosporine A (CSA), Mycophenolate mofetile (MMF),
and Rapamycin (RAPA) on Treg function both in vitro and in vivo
in a murine acute GVHD model. Treg reisolated from mixed
leucocyte reactions (MLR) containing CSA but not RAPA showed
signiﬁcantly reduced ability to suppress CD4CD25- T cell pro-
liferation in secondary MLRs (P  .025). The CSA effect could be
reversed to 85  3.4% by the addition of IL-2 (50 IU/ml) to the
primary culture. In vivo bioluminescence imaging (BLI) after ma-
jor mismatch BMT demonstrated reduced early proliferation of
donor derived luciferase-labeled conventional T-cells (Tcluc) in
animals treated with Treg. The addition of RAPA and to a lesser
extent MMF did not interfere with Treg function. Conversely,
combining Treg with CSA led to a signiﬁcantly increased Tcluc
proliferation (P  .002) indicating loss of Treg function. Treat-
ment with Treg/CSA was associated with increased GVHD risk
and poorest survival of the Treg/drug combinations. The Treg/
RAPA combination did not abrogate GVT effector function of
donor derived conventional T-cells against A20luc leukemia cells
as determined by BLI and histology. Our data indicate that CSA,
but not RAPA or MMF reduces Treg function possibly through an
IL-2 dependent mechanism. In vivo, the combination of Treg with
RAPA or MMF allowed for adequate GVHD suppression with
retention of GVT activity which may provide guidance for clinical
trials.
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PHARMACOKINETICS OF ANTI TUMOR NECROSIS FACTOR ANTIBODY
(INFLIXIMAB) IN CHILDREN WITH ACUTE GVHD INVOLVING THE GAS-
TROINTESTINAL TRACT
Sleight, B.1, Shenoy, S.2, Haight, A.3, Vora, R.4, Prabhakar, U.4,
Schultz, K.5, Gamis, A.6, Levine, J.7, Braun, T.7, Yanik, G.7 1. Yale
University, New Haven, CT; 2. Washington University, St. Louis, MO;
3 Emory University, Atlanta, GA; 4. Centocor, Inc., Malvern, PA; 5.
British Columbia Children’s Hospital, Vancouver, BC, Canada; 6. Chil-
dren’s Mercy Hospital, Kansas City, MO; 7. University of Michigan
Medical Center, Ann Arbor, MI.
Inﬂiximab (REMICADE®, Centocor), a chimeric anti-TNF

monoclonal antibody, has been used in the management of patients
with steroid-refractory acute GVHD. Though preliminary results
using inﬂiximab have been encouraging, the pharmacokinetics (Pk)
of inﬂiximab in this clinical setting have yet to be deﬁned. A
prospective trial examining the Pk of inﬂiximab in pediatric pa-
tients with gastrointestinal (GI) GVHD was undertaken. Five sub-
jects (median 11 yrs, range 9 mo–17 yrs) with GI GVHD were
enrolled. All subjects had histologic conﬁrmation of GVHD and
had failed 	 48 hours of corticosteroids prior to study entry.
Subjects received a single 5 mg/kg dose of inﬂiximab. PK and
pharmacodynamic samples were drawn at 16 time points (hours
0, 1, 2, 6, 24, 48, 96, weekly days 7–42, days 56, 70, 84). Based
upon existing Pk data in patients with Crohn’s disease, the time
required to reach a trough concentration 2 mcg/ml was the
deﬁned primary study endpoint. Results: Dosing was well tol-
erated in all ﬁve subjects. Inﬂiximab concentrations are as fol-
lows: Peak concentrations (Cmax) ranged from 64-160 mcg/ml
and were achieved by hours 2–6. Drug concentrations 	 20
mcg/ml were maintained for 	 7 days in all subjects. The
primary endpoint (trough concentration x 2 mcg/ml) was
reached on days 28, 35, 21, 35, and 7(asterisk) (median 28 days,
mean 25 days), respectively. Infectious complications with a
possible attribution to inﬂiximab included endocarditis on day
21 in 1 subject and CMV reactivation 1 month post inﬂiximab in
a second subject. No invasive fungal infections were seen. Du-
rable complete responses of GVHD were seen in 2 subjects by
days 7 and 28, respectively. Two subjects are alive (6 months and
16 months). Conclusion: In summary, pharmacokinetics of
inﬂiximab indicate that concentrations 	 the targeted threshold
level can be maintained for several weeks following a single 5
mg/kg dose in patients with GI GVHD. A phase II clinical trial,
with dosing intervals based upon these Pk parameters, will be
required. This investigator-initiated study was conducted
through the Pediatric Blood and Marrow Transplant Consor-
tium. Inﬂiximab and partial ﬁnancial support were provided by
Centocor, Inc.
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REDUCED-INTENSITY CONDITIONING PERMITS A SIGNIFICANT GRAFT
VS LEUKEMIA (GvL) EFFECT FOR ACUTE LEUKEMIA
Arellano, M., Flowers, C., Waller, E., Lonial, S., Kaufman, J.,
Winton, E., Khoury, H., Langston, A. Emory University, Atlanta, GA.
Delivering effective treatment for acute leukemia to older adults
remains a signiﬁcant challenge. Bone marrow/hematopoietic pro-
genitor cell transplant (HPCT) remains the only curative option
for relapsed/refractory or unfavorable risk disease. Myeloablative
conditioning regimens are associated with signiﬁcant morbidity
and mortality. The use of reduced intensity conditioning (RIC)
may offer a chance for cure, but whether RIC allows for a signif-
icant GvL effect is unclear. We report a single institution fol-
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low-up of 21 adult patients with acute leukemia treated with pe-
ripheral blood HPCT following RIC after being deemed
inadequate for fully myeloablative conditioning. A matched com-
parison arm of 42 consecutive patients transplanted after full my-
eloablative (FMA) conditioning is also reported. Methods: Be-
tween 1999–2004, 21 patients were treated with Fludarabine-based
conditioning prior to infusion of hematopoietic stem cells. Patients
were followed for toxicities and responses. IRB approval was ob-
tained prior to data collection. Kaplan-Meier estimates of survival
were performed. Patient disease characteristics were analyzed us-
ing T-tests to determine any factors that may be associated with
outcome and relapse. Signiﬁcant factors on univariate analysis were
placed into a Cox regression model for multivariable analysis.
Results: Patient characteristics: 76% of patients had AML and
24% had ALL. 14% of patients had relapsed or refractory disease
at transplant. A greater proportion of patients undergoing RIC,
had poor-risk cytogenetics. Median age was 56 yrs. 81% of patients
experienced clinically signiﬁcant acute or chronic GVHD. Overall
post-transplant survival was 29%. Twenty-nine percent (6/21) pa-
tients suffered relapse at a median of 4 months post-transplant.
Cox proportional hazards models for overall post-transplant sur-
vival and logistic regression models for relapse and overall survival
(N  63), showed that the only signiﬁcant predictor for OS and
relapse was cytogenetic risk group (P  .000). Of note, none of the
5 ALL patients transplanted after RIC have relapsed with a median
follow-up of 2.2 years (0.1–3.9 years); among 16 AML pts., 5 have
relapsed with median follow-up of 0.4 years (.1–2.2 years). These
results compare favorably to our cohort of pts. transplanted after
full myeloablative conditioning. Conclusion: The role of RIC
transplants for the treatment of high risk acute leukemia in older





N  21 (%)
Comparison
arm (FMA)
N  42 (%)
ALL 5 (24%) 10 (24%)
AML 16 (76%) 32 (76%)
Median age 56 (45–68) 52 (41–62)
Male 14 (67%) 20 (48%)
Disease status at
transplant:
CR1 13 (62%) 30 (71%)
CR2–3 4 (19%) 7 (17%)
Relapsed-
Refractory
3 (14%) 5 (12%)
Donor: Related 12 (57%) 34 (81%)
Unrelated 9 (43%) 8 (19%)
Cytogenetic risk: *
Favorable 1 (5%) 4 (10%)
Intermediate 6 (28%) 19 (45%)
Poor 14 (76%) 18 (43%)
*1 Pt, cytogenetics were unknown
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INVESTIGATING THE ROLE OF DENDRITIC CELLS IN EXTRACORPO-
REAL PHOTOPHERESIS USING AN IN VITRO MODEL
Holtick, U.1, Marshall, S.R.1, Wang, X.N.1, Hilkens, C.M.U.2,
Dickinson, A.M.1 1. Haematological Sciences; 2. Rheumatology, The
Medical School, University of Newcastle upon Tyne, United Kingdom.
Graft-versus-host disease (GvHD) is the major complication
after allogeneic transplantation and contributes signiﬁcantly to
transplant related mortality and morbidity. Especially steroid
refractory or steroid depending GvHD is linked to poor survival
or life quality. Conventional immunosuppression has very lim-
ited success in these conditions and increases susceptibility for
infection and relapse. Extracorporeal Photopheresis (ECP) is a
promising therapy for acute and chronic GvHD not responding
to conventional immunosuppressive therapy. ECP treatment
seems not to result in a pan-immunosuppression but has quite
selective effects on the pathogenic process in GvHD. The
mechanisms of action of ECP in GvHD known so far include
lymphocyte senescence or apoptosis and cytokine modulation.
Some groups report that antigen presenting cells like dendritic
cells (Dc) might be important for ECP mechanisms. We have
developed an in vitro model of ECP (in vitro PUVA) to inves-
tigate ECP effects on dendritic cells. Initial experiments have
shown the maturation of monocyte derived Dcs treated with in
vitro PUVA (upregulation of CD83, CD86, HLA-DR as well as
reduced endocytosis capacity), but also the induction of apopto-
sis. The stimulatory capacity of in vitro PUVA treated Dcs was
strongly inhibited in autologous and allogeneic MLR. However,
treatment of antigen-primed Dcs resulted in less inhibition,
suggesting factors that might preserve Dc stimulatory capaci-
ties. Immature Dcs, retrieved after coculture with in vitro
PUVA treated lymphocytes, show inhibited stimulatory capacity
on autologous and allogeneic T cells. Currently, we are inves-
tigating the changes in phenotype and cytokine pattern which
could transfer anergy or promote tolerance induction. In par-
allel, we are analyzing effects on monocyte-derived dendritic
cells from patients undergoing ECP treatment for chronic
GvHD. Dcs rendered tolerogenic could play a major role in
ECP mechanisms.
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HUMAN T LYMPHOCYTE ACTIVATION KINETICS FOR IDENTIFYING AND
TARGETING ALLOREACTIVE T CELLS
Bajwa, R.P.S., McCarthy, P.L., Wallace, P.K., Wallace, S., Wu, Y.,
Battiwalla, M. Roswell Park Cancer Institute, Buffalo, NY.
Selective depletion of alloreactive T cells from a stem cell graft
has the potential of reducing graft-versus-host disease (GvHD) while
preserving graft-versus-leukemia (GvL) and third party responses. For
this purpose several techniques generate and deplete alloreactive cells,
which are donor-derived T cells activated by recipient tissue. The
kinetics of T cell activation in donor-recipient co-culture systems is
critical in optimizing the timing of depletion of alloreactive T cells.
We present the T cell activation kinetics in our preclinical system.
Peripheral blood mononuclear cells (PBMCs) were derived form
several pairs of unrelated healthy human volunteers. 2500 cGy irra-
diated cells (stimulators) were co-cultured with PBMCs (responders)
in a 1:1 ratio and a concentration of 5  106/ml in serum free
medium. Stimulator cells were labeled with PKH67 and the co-
cultures were, analyzed for CD3, CD4, and CD25, expression by ﬂow
cytometry on days 0 through 7, using Topro-3 to exclude dead cells.
Our results show that CD3, CD4, CD25 cells (alloreactive CD8
cells) increased from 1 % on day 0, to 6.5 percent by day 5; the
addition of IL2 ampliﬁed the increment to nearly 10% by day 5.
CD3, CD4, CD25dim or total cells (CD4 activated T cells)
did not appreciably increase over time and ranged between 2 to
5%; the addition of IL2 did not have any effect. The CD3,
CD4, CD25bright cells (T regulatory cells) increased from
1% at baseline to 5% by day 5 and these were unaffected by
the addition of IL2. The proportion of non-activated T lym-
phocytes, decreased with time of co-culture progression. Our
results show that T lymphocyte activation, deﬁned by CD25
expression, progressively increases through the ﬁrst week of
co-culture. This important observation will help in establishing
the timing of allograft manipulation, for the selective depletion
of alloreactive T cells in clinical hematopoietic stem cell trans-
plantation.
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SIROLIMUS/MYCOPHENOLATE MOFETIL (MMF) AS TREATMENT FOR
GRAFT-VERSUS-HOST-DISEASE IN TWO CHILDREN WITH SEVERE RE-
NAL AND CALCINEURIN-INHIBITOR-ASSOCIATED CENTRAL NERVOUS
SYSTEM (CNS) TOXICITY
Ehlert, K., Groll, A.H., Vormoor, J. University Hospital, Department of
Pediatric Hematology and Oncology, Muenster, Germany.
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